Interleukin-35 induces regulatory B cells that suppress autoimmune disease

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 633-641

  Wang, Ren Xi ^a,c   Yu, Cheng Rong ^a   Dambuza, Ivy M ^a   Mahdi, Rashid M ^a   Dolinska, Monika B ^a   Sergeev, Yuri V ^a   Wingfield, Paul T ^b   Kim, Sung Hye ^a   Egwuagu, Charles E ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 27 RECEPTOR ALPHA; INTERLEUKIN 35 RECEPTOR; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 35; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE SEVERITY; HOST RESISTANCE; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; REGULATORY B CELL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH17 CELL;

MUS;

ADOPTIVE TRANSFER; ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES, REGULATORY; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; GENETIC ENGINEERING; IMMUNOPRECIPITATION; INTERLEUKIN-10; INTERLEUKIN-12 RECEPTOR BETA 2 SUBUNIT; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; UVEITIS;

EID: 84902078796     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3554     Document Type: Article

References (47)

1. Edwards, J.C. et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004). (Pubitemid 38758544)
2. Hu, C.Y. et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857-3867 (2007).
3. Yanaba, K. et al. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223, 284-299 (2008). (Pubitemid 351986191)
4. + T cell activation in mice. Proc. Natl. Acad. Sci. USA 104, 20878-20883 (2007).
5. Hamaguchi, Y. Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy. Nihon Rinsho Meneki Gakkai Kaishi 32, 29-34 (2009).
6. Pers, J.O. et al. B cell depletion and repopulation in autoimmune diseases. Clin. Rev. Allergy Immunol. 34, 50-55 (2008).
7. Bouaziz, J.D., Yanaba, K. & Tedder, T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224, 201-214 (2008).
8. + phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650 (2008). (Pubitemid 351636247)
9. Mauri, C. & Bosma, A. Immune regulatory function of B cells. Annu. Rev. Immunol. 30, 221-241 (2012).
10. Tadmor, T., Zhang, Y., Cho, H.M., Podack, E.R. & Rosenblatt, J.D. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol. Immunother. 60, 609-619 (2011).
11. Schioppa, T. et al. B regulatory cells and the tumor-promoting actions of TNF-A during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 108, 10662-10667 (2011).
12. Mauri, C. & Ehrenstein, M.R. The short history of regulatory B cells. Trends Immunol. 29, 34-40 (2008).
13. Berthelot, J.M. et al. Regulatory B cells play a key role in immune system balance. Joint Bone Spine 80, 18-22 (2013).
14. Yoshizaki, A. et al. Regulatory B cells control T cell autoimmunity through IL-21-dependent cognate interactions. Nature 491, 264-268 (2012).
15. Rafei, M. et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15, 1038-1045 (2009).
16. Collison, L.W. et al. The inhibitory cytokine IL-35 contributes to regulatory T cell function. Nature 450, 566-569 (2007). (Pubitemid 350190247)
17. Collison, L.W. et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093-1101 (2010).
18. Hunter, C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531 (2005). (Pubitemid 40961330)
19. Devergne, O., Birkenbach, M. & Kieff, E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. USA 94, 12041-12046 (1997). (Pubitemid 27467839)
20. Niedbala, W. et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 37, 3021-3029 (2007). (Pubitemid 350131282)
21. Caspi, R.R. A look at autoimmunity and inflammation in the eye. J. Clin. Invest. 120, 3073-3083 (2010).
22. Fillatreau, S., Gray, D. & Anderton, S.M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8, 391-397 (2008). (Pubitemid 351595221)
23. Carter, N.A. et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J. Immunol. 186, 5569-5579 (2011).
24. Ding, Q. et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 121, 3645-3656 (2011).
25. Nussenblatt, R.B. Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest. Ophthalmol. Vis. Sci. 32, 3131-3141 (1991).
26. Caspi, R.R. et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140, 1490-1495 (1988).
27. Vasconcellos, R., Carter, N.A., Rosser, E.C. & Mauri, C. IL-12p35 subunit contributes to autoimmunity by limiting IL-27-driven regulatory responses. J. Immunol. 187, 3402- 3412 (2011).
28. Collison, L.W. et al. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13, 290-299 (2012).
29. Tarrant, T.K., Silver, P.B., Chan, C.C., Wiggert, B. & Caspi, R.R. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J. Immunol. 161, 122-127 (1998). (Pubitemid 28285514)
30. Egwuagu, C.E., Charukamnoetkanok, P. & Gery, I. Thymic expression of autoantigens correlates with resistance to autoimmune disease. J. Immunol. 159, 3109-3112 (1997). (Pubitemid 127482066)
31. Shen, P. et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370 (2014).
32. Vignali, D.A. & Kuchroo, V.K. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13, 722-728 (2012).
33. Wang, R.X., Yu, C.R., Mahdi, R.M. & Egwuagu, C.E. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J. Biol. Chem. 287, 36012-36021 (2012).
34. Stumhofer, J.S. et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 11, 1119-1126 (2010).
35. Nussenblatt, R.B. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int. Rev. Immunol. 21, 273-289 (2002). (Pubitemid 34791944)
36. Olkhanud, P.B. et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res. 71, 3505-3515 (2011).
37. + T cells prevents development of experimental autoimmune diseases. J. Immunol. 180, 6070-6076 (2008).
38. Takase, H. et al. Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uveitis (EAU): potential neuroprotective role of SOCS proteins. J. Neuroimmunol. 168, 118-127 (2005). (Pubitemid 41396409)
39. + T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms. J. Immunol. 187, 3338-3346 (2011).
40. Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D. & Anderton, S.M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950 (2002). (Pubitemid 35154008)
41. Paques, M. et al. Panretinal, high-resolution color photography of the mouse fundus. Invest. Ophthalmol. Vis. Sci. 48, 2769-2774 (2007). (Pubitemid 351261232)
42. Xu, H. et al. A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images. Exp. Eye Res. 87, 319-326 (2008).
43. Chan, C.C. et al. Pathology of experimental autoimmune uveoretinitis in mice. J. Autoimmun. 3, 247-255 (1990).
44. Amadi-Obi, A. et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13, 711-718 (2007). (Pubitemid 46889754)
45. Yu, C.R., Lee, Y.S., Mahdi, R.M., Surendran, N. & Egwuagu, C.E. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS ONE 7, e29742 (2012).
46. Li, W., Nagineni, C.N., Hooks, J.J., Chepelinsky, A.B. & Egwuagu, C.E. Interferon-g signaling in human retinal pigment epithelial cells mediated by STAT1, ICSBP, and IRF-1 transcription factors. Invest. Ophthalmol. Vis. Sci. 40, 976-982 (1999). (Pubitemid 29153264)
47. Oh, H.M. et al. STAT3 protein promotes T cell survival and inhibits interleukin-2 production through up-regulation of class O Forkhead transcription factors. J. Biol. Chem. 286, 30888-30897 (2011).